David E Kandzari1, Pieter C Smits2, Michael P Love2, Ori Ben-Yehuda2, Shmuel Banai2, Simon D Robinson2, Michael Jonas2, Ran Kornowski2, Rodrigo Bagur2, Andres Iniguez2, Haim Danenberg2, Robert Feldman2, Rajiv Jauhar2, Harish Chandna2, Manish Parikh2, Gidon Y Perlman2, Mercedes Balcells2, Peter Markham2, Melek Ozgu Ozan2, Philippe Genereux2, Elazer R Edelman2, Martin B Leon2, Gregg W Stone2. 1. From Piedmont Heart Institute, Atlanta, GA (D.E.K.); Maasstad Hospital, Rotterdam, The Netherlands (P.C.S.); Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia (M.P.L.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York (O.B.-Y., M.P., M.O.O., P.G., M.B.L., G.W.S.); Tel Aviv Medical Center, Israel (S.B.); Victoria Heart Institute Foundation, British Columbia, Canada (S.D.R.); Kaplan Medical Center, Rehovot, Israel (M.J.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Centre Hospitalier Universitaire de Quebec, Canada (R.B.); Hospital Meixoeiro, Vigo, Spain (A.I.); Hadassah Hebrew University Medical Center, Jerusalem, Israel (H.D., G.Y.P.); MediQuest Research Group, Ocala, FL (R.F.); North Shore University Hospital, New York (R.J.); Victoria Heart and Vascular Center, TX (H.C.); Medinol Ltd, Tel Aviv, Israel (G.Y.P.); Massachusetts Institute of Technology, Cambridge (M.B., E.R.E.); and CBSET Inc, Lexington, MA (P.M.). david.kandzari@piedmont.org. 2. From Piedmont Heart Institute, Atlanta, GA (D.E.K.); Maasstad Hospital, Rotterdam, The Netherlands (P.C.S.); Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia (M.P.L.); Columbia University Medical Center and the Cardiovascular Research Foundation, New York (O.B.-Y., M.P., M.O.O., P.G., M.B.L., G.W.S.); Tel Aviv Medical Center, Israel (S.B.); Victoria Heart Institute Foundation, British Columbia, Canada (S.D.R.); Kaplan Medical Center, Rehovot, Israel (M.J.); Rabin Medical Center, Petach Tikva, Israel (R.K.); Centre Hospitalier Universitaire de Quebec, Canada (R.B.); Hospital Meixoeiro, Vigo, Spain (A.I.); Hadassah Hebrew University Medical Center, Jerusalem, Israel (H.D., G.Y.P.); MediQuest Research Group, Ocala, FL (R.F.); North Shore University Hospital, New York (R.J.); Victoria Heart and Vascular Center, TX (H.C.); Medinol Ltd, Tel Aviv, Israel (G.Y.P.); Massachusetts Institute of Technology, Cambridge (M.B., E.R.E.); and CBSET Inc, Lexington, MA (P.M.).
Abstract
BACKGROUND: The safety and efficacy of a novel cobalt alloy-based coronary stent with a durable elastomeric polymer eluting the antiproliferative agent ridaforolimus for treatment of patients with coronary artery disease is undetermined. METHODS: A prospective, international 1:1 randomized trial was conducted to evaluate in a noninferiority design the relative safety and efficacy of ridaforolimus-eluting stents (RESs) and slow-release zotarolimus-eluting stents among 1919 patients undergoing percutaneous coronary intervention at 76 centers. Inclusion criteria allowed enrollment of patients with recent myocardial infarction, total occlusions, bifurcations lesions, and other complex conditions. RESULTS:Baseline clinical and angiographic characteristics were similar between the groups. Overall, mean age was 63.4 years, 32.5% had diabetes mellitus, and 39.7% presented with acute coronary syndromes. At 12 months, the primary end point of target lesion failure (composite of cardiac death, target vessel-related myocardial infarction, and target lesion revascularization) was 5.4% for both devices (upper bound of 1-sided 95% confidence interval 1.8%, Pnoninferiority=0.001). Definite/probable stent thrombosis rates were low in both groups (0.4% RES versus 0.6% zotarolimus-eluting stent, P=0.75); 13-month angiographic in-stent late lumen loss was 0.22±0.41 mm and 0.23±0.39 mm (Pnoninferiority=0.004) for the RES and zotarolimus-eluting stent groups, respectively, and intravascular ultrasound percent neointimal hyperplasia was 8.10±5.81 and 8.85±7.77, respectively (Pnoninferiority=0.01). CONCLUSIONS: In the present trial, which allowed broad inclusion criteria, the novel RESs met the prespecified criteria for noninferiority compared with zotarolimus-eluting stents for the primary end point of target lesion failure at 12 months and had similar measures of late lumen loss. These findings support the safety and efficacy of RESs in patients who are representative of clinical practice. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01995487.
RCT Entities:
BACKGROUND: The safety and efficacy of a novel cobalt alloy-based coronary stent with a durable elastomeric polymer eluting the antiproliferative agent ridaforolimus for treatment of patients with coronary artery disease is undetermined. METHODS: A prospective, international 1:1 randomized trial was conducted to evaluate in a noninferiority design the relative safety and efficacy of ridaforolimus-eluting stents (RESs) and slow-release zotarolimus-eluting stents among 1919 patients undergoing percutaneous coronary intervention at 76 centers. Inclusion criteria allowed enrollment of patients with recent myocardial infarction, total occlusions, bifurcations lesions, and other complex conditions. RESULTS: Baseline clinical and angiographic characteristics were similar between the groups. Overall, mean age was 63.4 years, 32.5% had diabetes mellitus, and 39.7% presented with acute coronary syndromes. At 12 months, the primary end point of target lesion failure (composite of cardiac death, target vessel-related myocardial infarction, and target lesion revascularization) was 5.4% for both devices (upper bound of 1-sided 95% confidence interval 1.8%, Pnoninferiority=0.001). Definite/probable stent thrombosis rates were low in both groups (0.4% RES versus 0.6% zotarolimus-eluting stent, P=0.75); 13-month angiographic in-stent late lumen loss was 0.22±0.41 mm and 0.23±0.39 mm (Pnoninferiority=0.004) for the RES and zotarolimus-eluting stent groups, respectively, and intravascular ultrasound percent neointimal hyperplasia was 8.10±5.81 and 8.85±7.77, respectively (Pnoninferiority=0.01). CONCLUSIONS: In the present trial, which allowed broad inclusion criteria, the novel RESs met the prespecified criteria for noninferiority compared with zotarolimus-eluting stents for the primary end point of target lesion failure at 12 months and had similar measures of late lumen loss. These findings support the safety and efficacy of RESs in patients who are representative of clinical practice. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01995487.
Authors: Patrick W Serruys; Sigmund Silber; Scot Garg; Robert Jan van Geuns; Gert Richardt; Pawel E Buszman; Henning Kelbaek; Adrianus Johannes van Boven; Sjoerd H Hofma; Axel Linke; Volker Klauss; William Wijns; Carlos Macaya; Philippe Garot; Carlo DiMario; Ganesh Manoharan; Ran Kornowski; Thomas Ischinger; Antonio Bartorelli; Jacintha Ronden; Marco Bressers; Pierre Gobbens; Manuela Negoita; Frank van Leeuwen; Stephan Windecker Journal: N Engl J Med Date: 2010-06-16 Impact factor: 91.245
Authors: Mounir W Z Basalus; Marc J K Ankone; Gert K van Houwelingen; Frits H A F de Man; Clemens von Birgelen Journal: EuroIntervention Date: 2009-05 Impact factor: 6.534
Authors: Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White; Hugo A Katus; Bertil Lindahl; David A Morrow; Peter M Clemmensen; Per Johanson; Hanoch Hod; Richard Underwood; Jeroen J Bax; Robert O Bonow; Fausto Pinto; Raymond J Gibbons; Keith A Fox; Dan Atar; L Kristin Newby; Marcello Galvani; Christian W Hamm; Barry F Uretsky; Ph Gabriel Steg; William Wijns; Jean-Pierre Bassand; Phillippe Menasché; Jan Ravkilde; E Magnus Ohman; Elliott M Antman; Lars C Wallentin; Paul W Armstrong; Maarten L Simoons; James L Januzzi; Markku S Nieminen; Mihai Gheorghiade; Gerasimos Filippatos; Russell V Luepker; Stephen P Fortmann; Wayne D Rosamond; Dan Levy; David Wood; Sidney C Smith; Dayi Hu; José-Luis Lopez-Sendon; Rose Marie Robertson; Douglas Weaver; Michal Tendera; Alfred A Bove; Alexander N Parkhomenko; Elena J Vasilieva; Shanti Mendis Journal: Circulation Date: 2012-08-24 Impact factor: 29.690
Authors: Dean J Kereiakes; Ian T Meredith; Stephan Windecker; R Lee Jobe; Shamir R Mehta; Ian J Sarembock; Robert L Feldman; Bernardo Stein; Christophe Dubois; Timothy Grady; Shigeru Saito; Takeshi Kimura; Thomas Christen; Dominic J Allocco; Keith D Dawkins Journal: Circ Cardiovasc Interv Date: 2015-04 Impact factor: 6.546
Authors: Tullio Palmerini; Giuseppe Biondi-Zoccai; Diego Della Riva; Andrea Mariani; Manel Sabaté; Pieter C Smits; Christoph Kaiser; Fabrizio D'Ascenzo; Giacomo Frati; Massimo Mancone; Philippe Genereux; Gregg W Stone Journal: J Am Coll Cardiol Date: 2013-11-06 Impact factor: 24.094
Authors: Ian T Meredith; Stephen Worthley; Robert Whitbourn; Darren L Walters; Dougal McClean; Mark Horrigan; Jeffrey J Popma; Donald E Cutlip; Ann DePaoli; Manuela Negoita; Peter J Fitzgerald Journal: JACC Cardiovasc Interv Date: 2009-10 Impact factor: 11.195
Authors: Ian T Meredith; Stephen Worthley; Robert Whitbourn; Darren Walters; Jeff Popma; Don Cutlip; Peter Fitzgerald Journal: EuroIntervention Date: 2007-05 Impact factor: 6.534
Authors: Sripal Bangalore; Sunil Kumar; Mario Fusaro; Nicholas Amoroso; Michael J Attubato; Frederick Feit; Deepak L Bhatt; James Slater Journal: Circulation Date: 2012-05-14 Impact factor: 29.690
Authors: Issam D Moussa; Lloyd W Klein; Binita Shah; Roxana Mehran; Michael J Mack; Emmanouil S Brilakis; John P Reilly; Gilbert Zoghbi; Elizabeth Holper; Gregg W Stone Journal: J Am Coll Cardiol Date: 2013-10-22 Impact factor: 24.094
Authors: Maayan Konigstein; Mahesh V Madhavan; Ori Ben-Yehuda; Hussein M Rahim; Iva Srdanovic; Fotis Gkargkoulas; Ghazaleh Mehdipoor; Evan Shlofmitz; Akiko Maehara; Björn Redfors; Ankita K Gore; Thomas McAndrew; Gregg W Stone; Ziad A Ali Journal: Am Heart J Date: 2019-04-12 Impact factor: 4.749
Authors: Joseph Robert Stevens; Ava Zamani; James Ian Atkins Osborne; Reza Zamani; Mohammad Akrami Journal: Biomed Eng Online Date: 2021-05-08 Impact factor: 2.819
Authors: Philip Urban; Roxana Mehran; Roisin Colleran; Dominick J Angiolillo; Robert A Byrne; Davide Capodanno; Thomas Cuisset; Donald Cutlip; Pedro Eerdmans; John Eikelboom; Andrew Farb; C Michael Gibson; John Gregson; Michael Haude; Stefan K James; Hyo-Soo Kim; Takeshi Kimura; Akihide Konishi; John Laschinger; Martin B Leon; P F Adrian Magee; Yoshiaki Mitsutake; Darren Mylotte; Stuart Pocock; Matthew J Price; Sunil V Rao; Ernest Spitzer; Norman Stockbridge; Marco Valgimigli; Olivier Varenne; Ute Windhoevel; Robert W Yeh; Mitchell W Krucoff; Marie-Claude Morice Journal: Eur Heart J Date: 2019-08-14 Impact factor: 29.983
Authors: Philip Urban; Roxana Mehran; Roisin Colleran; Dominick J Angiolillo; Robert A Byrne; Davide Capodanno; Thomas Cuisset; Donald Cutlip; Pedro Eerdmans; John Eikelboom; Andrew Farb; C Michael Gibson; John Gregson; Michael Haude; Stefan K James; Hyo-Soo Kim; Takeshi Kimura; Akihide Konishi; John Laschinger; Martin B Leon; P F Adrian Magee; Yoshiaki Mitsutake; Darren Mylotte; Stuart Pocock; Matthew J Price; Sunil V Rao; Ernest Spitzer; Norman Stockbridge; Marco Valgimigli; Olivier Varenne; Ute Windhoevel; Robert W Yeh; Mitchell W Krucoff; Marie-Claude Morice Journal: Circulation Date: 2019-05-22 Impact factor: 29.690